Anti-SARS-Cov-2 antibodies derived from 3bgf
US11028167B1 · kind B1 · utility
6Cited by
0References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 14, 2020 |
| Grant date | Jun 8, 2021 |
| Priority date | — |
| Expiry date | May 14, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/165
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure provides antibodies and antigen-binding fragments that are derived from 3bgf and that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments herein can be used to diagnose a SARS CoV-2 infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.